NTx Bio Advances Personalized Cancer Vaccine Manufacturing
Rio Rancho, New Mexico, August 19, 2026 NTx Bio is advancing the manufacturing infrastructure supporting personalized cancer vaccines through...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Rio Rancho, New Mexico, August 19, 2026 NTx Bio is advancing the manufacturing infrastructure supporting personalized cancer vaccines through...
AUSTIN, Texas | May 2026 Natera, Inc. announced a new collaboration with Diakonos Oncology Corp. to utilize its personalized...
HOUSTON, May 6, 2026 Diakonos Oncology Corp., a clinical-stage biotechnology company focused on next-generation cancer immunotherapies, has announced that...
